Previous close | 0.0500 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.1000 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 0.0500 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 555 |
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessme
Q1 2024 Bionano Genomics Inc Earnings Call
Explore key financial outcomes and strategic insights from Bionano Genomics' first quarter of 2024, highlighting revenue increases, product updates, and future prospects.